Growth hormone control may be important HIV lipodystrophy treatment

Study describes new approach to treating AIDS-associated syndrome

Increasing the body’s production of growth hormone may be an effective treatment for HIV lipodystrophy, a syndrome involving the redistribution of fat and other metabolic changes in those receiving combination drug therapy for HIV infection. Researchers from Massachusetts General Hospital (MGH) report that administration of growth-hormone-releasing hormone to a group of men with HIV lipodystrophy significantly improved fat distribution with no negative side effects. The study appears in the July 14 Journal of the American Medical Association, a special HIV/AIDS issue published in conjunction with the International AIDS Conference in Bangkok.

“This study is an initial proof of principal that augmenting low growth hormone levels in this way has the potential to reverse the abnormal body composition seen in these individuals,” says Steven Grinspoon, MD, of the MGH Neuroendocrine Unit and Program in Nutritional Metabolism, the report’s senior author. “At the current time, there is no established treatment for this syndrome.”

The combination drug strategy known as highly active antiretroviral therapy (HAART) can significantly reduce virus levels and help maintain health in HIV-infected individuals, but more than half may develop lipodystrophy. Typical symptoms of the syndrome include a loss of subcutaneous fat in the face, arms, and legs and increased fat deposits in the abdomen and upper back. The metabolic aspects of the syndrome – changes in cholesterol and other blood lipids, and development of insulin resistance – could also increase the risk of cardiovascular disease.

It recently has been discovered that men with lipodystrophy do not secrete normal levels of growth hormone. Although growth-hormone (GH) injections can reduce fat deposits that develop in other GH-deficiency situations, high-dose injections have a number of significant side effects, including insulin resistance, already a problem for lipodystrophy patients.

In a healthy body, secretion of GH is controlled by a feedback mechanism, which shuts down the process if hormone concentrations exceed normal blood levels. Directly injecting GH could bypass this natural control mechanism, allowing blood levels to rise too high. In an attempt to raise GH levels in a more natural manner, the MGH team devised a strategy using growth-hormone-releasing hormone (GHRH).

They enrolled 31 men with HIV lipodystrophy for a 12-week, randomized, double-blinded study. Participants injected themselves twice daily with either GHRH or a placebo injection. To track GH secretion, the researchers measured blood levels of insulin-like growth factor-1 (IGF-1). As part of the natural feedback system, IGF-1 levels rise in response to GH blood levels, which turns off further hormone secretion. Body composition was measured by x-ray and CT scan studies, and blood tests followed other metabolic markers.
At the end of the study period, participants in the GHRH group had significant increases in their IGF-1 levels compared with the placebo group, indicating more normal GH production and regulation. In addition, body composition of those in the GHRH group returned to a more normal pattern, with increases in subcutaneous fat in the extremities and less fat deposited deep within the abdomen. Although there were no significant differences in total fat mass, those in the GHRH group had significant increases in lean body mass.

As the reseachers hoped, the increased GH levels resulting from GHRH therapy did not significantly change blood levels of insulin and glucose. Cholesterol and triglyceride levels also remained stable. In addition, both participants and their physicians noted improvement in lipodystrophy symptoms in the GHRH group, and those participants also expressed significantly greater satisfaction with their overall appearance.

“The novel part of this study was use of a natural secretion inducer to produce normal hormone levels,” Grinspoon says. “The significant redistribution of fat away from the abdomen reflects a change toward a more healthy cardiovascular profile, an important health benefit with minimal risk due to the achievement of normal growth hormone levels.” Grinspoon is an associate professor of Medicine at Harvard Medical School.

The researchers note that further studies should investigate longer-term therapy in a larger, more diverse population. They also are studying other GH-secretion inducers and theorize that this approach could be useful for other GH-deficiency syndromes. Although GHRH remains investigational for lipodystrophy, the study was performed with the approval of the Food and Drug Administration.